Midterm outcomes of paclitaxel-eluting stents for the treatment of intracranial posterior circulation stenoses

J Neurosurg. 2007 Feb;106(2):222-5. doi: 10.3171/jns.2007.106.2.222.

Abstract

Object: Symptomatic intracranial vertebral and basilar artery atherosclerotic stenoses carry a high risk of stroke and permanent disability if refractory to maximal medical therapy. The authors conducted a study to determine the technical feasibility and midterm clinical and angiographic outcomes in patients in whom paclitaxel-eluting stents were placed for the treatment of symptomatic intracranial posterior circulation stenoses.

Methods: A retrospective review of medical records and imaging studies was performed for 13 consecutive patients in whom paclitaxel-coated stents were used to treat symptomatic posterior circulation intracranial stenoses between 2002 and 2005. Clinical follow-up data were supplemented by telephone interviews. The technical success rate for stent placement was 100%. One patient (8%) suffered a periprocedural stroke. Twelve patients (92%) underwent clinical follow up for a minimum of 3 months postsurgery, and 11 (92%) of these patients remained asymptomatic after a mean period of 10.9 months. Nine patients (69%) underwent catheter angiographic follow up, and no patient had significant in-stent recurrence of stenosis after a mean period of 5.4 months.

Conclusions: Treatment of intracranial posterior circulation stenoses with drug-eluting stents is technically feasible, and the rate of clinically significant periprocedural complications is low. Rates of stenosis recurrence are reduced compared with those of bare-metal stents in the midterm. Midterm clinical outcome is excellent; no symptom recurrence was observed in this patient cohort.

MeSH terms

  • Adult
  • Aged
  • Angioplasty*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage*
  • Retrospective Studies
  • Stents*
  • Time Factors
  • Treatment Outcome
  • Tubulin Modulators / administration & dosage*
  • Vertebrobasilar Insufficiency / surgery*

Substances

  • Tubulin Modulators
  • Paclitaxel